Wealth Enhancement Advisory Services
KYMR icon

Wealth Enhancement Advisory Services’s Kymera Therapeutics KYMR Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$81.5K Buy
+3,103
New +$355K ﹤0.01% 3968

Other funds holding KYMR

NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CIA
Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

Wealth Enhancement Advisory Services's KYMR Position: Q3 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Kymera Therapeutics (KYMR) in Q3 2026: 3,103 shares worth $81.5K. The stake represents ﹤0.01% of the portfolio and ranks #3968 among its holdings.

7 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Wealth Enhancement Advisory Services held 3,103 shares of Kymera Therapeutics worth $81.5K as of Q3 2026.
  • Kymera Therapeutics was a new Wealth Enhancement Advisory Services position in Q3 2026.
  • Kymera Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3968 holding.
  • 7 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.